Cartalax vs Low-Dose Naltrexone (LDN)
A side-by-side research comparison of Cartalax and Low-Dose Naltrexone (LDN) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cartalax | Low-Dose Naltrexone (LDN) |
|---|---|---|
| Full name | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) | Low-Dose Naltrexone |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound (peptide bioregulator) | Off-label prescription |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. | Brief nocturnal opioid receptor blockade triggers compensatory upregulation of endogenous opioid production and OGF (opioid growth factor), modulating immune cell proliferation and reducing inflammatory cytokines. |
| Molecular weight | ~390 Da | 341.40 Da |
| Half-life | Short (peptide) | ~4 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~5-40% oral (first-pass) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1.5-4.5 mg |
| Frequency | Once daily | Nightly at bedtime |
| Route | Oral capsule or subcutaneous | Oral capsule (compounded) |
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Low-Dose Naltrexone (LDN) reported benefits
- Immune modulation
- Reduced inflammation
- Chronic pain relief
- Autoimmune support
- Improved mood via endorphins
- Weight loss support
Related comparisons
Research and educational reference only. Not medical advice.